Delix Therapeutics raises $100m for zalsupindole development
Delix plans to advance Zalsupindole toward a Phase II placebo-controlled trial in early 2027.
Drug Development
Charles River agrees $470m deal for Frontage assets
Network Bio partners with Duke University on AI disease models
Bio-Thera gains Chinese approval for spondylitis and rheumatoid arthritis drug
Armada to combine with Brains Bioceutical in $750m deal
Alfasigma receives EC’s expanded approval for filgotinib to treat axSpA
Evommune signs $1.1bn licence deal with Hinova for EVO570
PharmatrophiX and Circular partner on neurodegenerative drugs
